August 14, 2024
Sponsored by Thermo Fisher Scientific
This white paper provides a detailed analysis of the challenges associated with in-house buffer and process liquid preparation in bioprocessing operations. Key points include:
Operational inefficiencies, contamination risks, batch failures, and the financial burdens associated with these processes can result in production delays and increased costs.
Significant capital and operational expenditures are involved in warehouse space, equipment, and personnel.
The paper presents a case study of a clinical-stage biotherapeutics company:
The company faced challenges in scaling its manufacturing operations for immunotherapy development.
By outsourcing buffer manufacturing to Thermo Fisher Scientific, the company avoided significant capital expenditures and improved lead times.
The white paper emphasizes the benefits of outsourcing buffer preparation:
Experienced partners can manage supply chains, ensure quality standards, mitigate supply disruptions, increase order accuracy, and improve productivity.
They can provide ready-to-use process liquids and buffers in bioprocess containers, handle multiple buffer solution calculations, perform audits, and test multiple lots.
The paper concludes with the potential for significant savings and improvements:
Outsourcing can result in significant savings in capital and operational expenditures and improvements in workflow efficiencies.
Thermo Fisher Scientific can provide key insights across process workflows, helping businesses focus on producing life-changing therapies.
You May Also Like
